为解决物联网快速收敛算法存在的收敛性能较差、网络稳定时间较短的不足,提出了基于拓扑区域一体化成型映射机制的物联网快速收敛算法。首先,根据物联网节点分布具有的随机分布特性及泊松分布特性,通过聚类方式来构建聚合度-权重值裁决...为解决物联网快速收敛算法存在的收敛性能较差、网络稳定时间较短的不足,提出了基于拓扑区域一体化成型映射机制的物联网快速收敛算法。首先,根据物联网节点分布具有的随机分布特性及泊松分布特性,通过聚类方式来构建聚合度-权重值裁决模型,以实现路由的稳定收敛,消除因簇头节点失效而导致的区域上传缓慢的现象;随后,采用退避机制来提升簇头节点的传输性能,有效降低因能量受限而导致的网络传输缓慢的现象,优化路由收敛性能,降低因路由抖动而导致的网络瘫痪概率。仿真实验结果表明:与常见的时间度一体化物联网收敛算法(Convergence Algorithm for Time-Integrated Internet of Things,TI-IOT算法)、路由集中度快速收敛算法(A Fast Convergence Algorithm for Routing Concentration Degree,RCD算法)相比,所提算法具有更高的网络稳定工作时间及较快的收敛速度,以及更小的路由冗余度。展开更多
Renal tubulointerstitial fibrosis is the common ending of progressive renal disease. It is worth developing new ways to stop the progress of renal fibrosis. Peroxisome proliferator-activated receptor-γ（PPARγ） agon...Renal tubulointerstitial fibrosis is the common ending of progressive renal disease. It is worth developing new ways to stop the progress of renal fibrosis. Peroxisome proliferator-activated receptor-γ（PPARγ） agonists have been studied to treat diabetic nephropathy, cisplatin-induced acute renal injury, ischemia reperfusion injury and adriamycin nephropathy. In this study, unilateral ureteral obstruction（UUO） was used to establish a different renal fibrosis model. PPARγ agonist pioglitazone was administrated by oral gavage and saline was used as control. At 7th and 14 th day after the operation, mice were sacrificed for fibrosis test and T lymphocytes subsets test. Unexpectedly, through MASSON staining, immunohistochemistry for α-SMA, and Western blotting for α-SMA and PDGFR-β, we found that pioglitazone failed to attenuate renal fibrosis in UUO mice. However, flow cytometry showed that pioglitazone down-regulated Th1 cells, and up-regulated Th2 cells, Th17 cells and Treg cells. But the Th17/Treg ratio had no significant change by pioglitazone. Real-time PCR results showed that TGF-β and MCP-1 had no significant changes, at the same time, CD4＋ T cells associated cytokines were partially regulated by pioglitazone pretreatment. Taken together, pioglitazone failed to suppress renal fibrosis progression caused by UUO.展开更多
文摘为解决物联网快速收敛算法存在的收敛性能较差、网络稳定时间较短的不足,提出了基于拓扑区域一体化成型映射机制的物联网快速收敛算法。首先,根据物联网节点分布具有的随机分布特性及泊松分布特性,通过聚类方式来构建聚合度-权重值裁决模型,以实现路由的稳定收敛,消除因簇头节点失效而导致的区域上传缓慢的现象;随后,采用退避机制来提升簇头节点的传输性能,有效降低因能量受限而导致的网络传输缓慢的现象,优化路由收敛性能,降低因路由抖动而导致的网络瘫痪概率。仿真实验结果表明:与常见的时间度一体化物联网收敛算法(Convergence Algorithm for Time-Integrated Internet of Things,TI-IOT算法)、路由集中度快速收敛算法(A Fast Convergence Algorithm for Routing Concentration Degree,RCD算法)相比,所提算法具有更高的网络稳定工作时间及较快的收敛速度,以及更小的路由冗余度。
基金financially supported by grants from the National Natural Science Foundation of China(No.81470948,No.81270770,and No.81300575)Hubei Provincial Health and Family Planning Youth Project of China(No.WJ2015Q007)
文摘Renal tubulointerstitial fibrosis is the common ending of progressive renal disease. It is worth developing new ways to stop the progress of renal fibrosis. Peroxisome proliferator-activated receptor-γ（PPARγ） agonists have been studied to treat diabetic nephropathy, cisplatin-induced acute renal injury, ischemia reperfusion injury and adriamycin nephropathy. In this study, unilateral ureteral obstruction（UUO） was used to establish a different renal fibrosis model. PPARγ agonist pioglitazone was administrated by oral gavage and saline was used as control. At 7th and 14 th day after the operation, mice were sacrificed for fibrosis test and T lymphocytes subsets test. Unexpectedly, through MASSON staining, immunohistochemistry for α-SMA, and Western blotting for α-SMA and PDGFR-β, we found that pioglitazone failed to attenuate renal fibrosis in UUO mice. However, flow cytometry showed that pioglitazone down-regulated Th1 cells, and up-regulated Th2 cells, Th17 cells and Treg cells. But the Th17/Treg ratio had no significant change by pioglitazone. Real-time PCR results showed that TGF-β and MCP-1 had no significant changes, at the same time, CD4＋ T cells associated cytokines were partially regulated by pioglitazone pretreatment. Taken together, pioglitazone failed to suppress renal fibrosis progression caused by UUO.
